Biometrics giant, Zimmer, finalizes purchase of Monogram Technologies for a sum of $177 million in a recent deal.

Zimmer Biomet to Acquire Monogram Technologies in a $177 Million Deal

In a significant move, global medical technology leader Zimmer Biomet has agreed to acquire Monogram Technologies, an orthopedic robotics company, for approximately $177 million in equity value. The acquisition, which is subject to regulatory and stockholder approvals, is expected to close later this year.

Monogram Technologies, advised by Houlihan Lokey, is developing a fully autonomous version of its robotic technology. This groundbreaking technology is set to make Zimmer Biomet the first company in orthopedics to offer a fully autonomous surgical robot.

Wells Fargo Securities is serving as the exclusive financial advisor to Monogram, while Duane Morris is serving as the legal advisor. On the other hand, Morgan Stanley is serving as the exclusive financial advisor to Zimmer Biomet, and Hogan Lovells is serving as the legal advisor.

Ivan Tornos, Chairman, President, and CEO of Zimmer Biomet, expressed his excitement about the acquisition. He stated that Monogram's technology is a significant advancement, demonstrating Zimmer Biomet's commitment to being the boldest and broadest innovator in surgical robotics and navigation. With Monogram's proprietary technology, Zimmer Biomet has the potential to become the first company to deliver fully autonomous capabilities and redefine both the standard of care and the future of orthopedic surgery.

Benjamin Sexson, CEO of Monogram, shared similar sentiments. He expressed that his company has been focused on advancing orthopedic robotics with technology designed to safely, efficiently, and accurately support surgeons with total knee arthroplasty. He is excited about adding Monogram's technology to Zimmer Biomet's leading portfolio of surgical robotics, navigation solutions, and trusted implants, and benefiting from their deep industry expertise and global scale.

The acquisition is expected to be neutral to adjusted earnings per share in 2025-2027 and accretive from 2028 onward. Monogram's CT-based, semi-autonomous, AI-navigated total knee arthroplasty (TKA) robotic technology, which received FDA 510(k) clearance in March 2025, is expected to be commercialized with Zimmer Biomet implants in early 2027.

Upon closing, Monogram's semi- and fully autonomous robotic technologies will be integrated into Zimmer Biomet's ROSA Robotics platform. This integration is expected to further strengthen Zimmer Biomet's customer-centric portfolio, making it the most comprehensive and flexible technology ecosystem to support the varying preferences of a vast array of surgeons.

Monogram stockholders will receive a non-tradeable contingent value right (CVR) potentially worth up to $12.37 per share based on future milestones. The transaction, advised by J.P. Morgan for Zimmer Biomet, is expected to redefine the future of orthopedic surgery and solidify Zimmer Biomet's position as a global leader in medical technology.

Biometrics giant, Zimmer, finalizes purchase of Monogram Technologies for a sum of $177 million in a recent deal.